Jarushka Naidoo shared a post on X:

“RomeLung24

Tony Mok presents key insights on neoadj chemoIO and goes back to basics to chart a path forward: – which pts don’t benefit? PDL1<1%, KRAS/STK11, non PR – how do we measure benefit? MPR, pathCR similar – will MRD refine tx? Platform will matter.”

Source: Jarushka Naidoo/X

Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland. She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials. She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.